Recent performance snapshot

Illumina (ILMN) has drawn investor attention after recent trading, with the stock last closing at US$141.92 and sitting on an intrinsic discount estimate of about 43% relative to one valuation model.

Over the past month the stock shows a 6.8% return, and over the past 3 months it is up about 18.3%. On a 1 year basis the total return stands near 78.8%, while the 3 year and 5 year total returns show declines of roughly 31.3% and 63.3% respectively.

For context, Illumina’s recent 30 day share price return of 6.8% builds on a 90 day share price return of 18.3%, while the 1 year total shareholder return of 78.8% contrasts with declines over the 3 and 5 year periods. As a result, current momentum sits firmly at the short term end of the spectrum.

If Illumina’s recent move has you looking more broadly at genomic and medical data trends, it can be useful to see what else is gaining attention across 30 healthcare AI stocks

With Illumina trading near US$141.92 against an intrinsic value estimate that points to a sizeable discount, the key question is whether this represents a genuine mispricing or a stock that already reflects future growth expectations.

Most Popular Narrative: 4.3% Overvalued

Illumina’s last close of $141.92 sits slightly above the most followed fair value estimate of $136.11, which is built using a discount rate of 8.1%.

Ongoing innovation, multiomics expansion, and operational efficiency are enhancing gross margins and creating new growth opportunities.

Strategic expansion into multiomics, notably the planned acquisition of SomaLogic and integration of proteomics capabilities, creates incremental growth opportunities by increasing the breadth of Illumina's data and platform offerings, contributing to future revenue and operating margin expansion. Read the complete narrative.

Want to see what kind of revenue path and margin profile that fair value hinges on? The narrative leans on steady top line growth, improving profitability, and a future earnings multiple that assumes Illumina keeps earning its place in clinical genomics.

Result: Fair Value of $136.11 (OVERVALUED)

However, this picture could shift if research funding softens further, or if Chinese regulatory pressures weigh more heavily on instrument and consumables demand.

Another View: Earnings Multiple Sends a Different Signal

While the most popular fair value narrative sees Illumina as about 4.3% overvalued relative to a US$136.11 target, the current P/E of 25.2x tells a different story. It sits below the global Life Sciences average of 35.1x and a peer average of 27.6x, yet above a fair ratio of 20.3x.

In practice, that means the stock trades cheaper than many sector peers, but at a premium to where the fair ratio suggests the market could eventually settle. This raises the question of whether sentiment or fundamentals will set the tone from here.

Next Steps

With mixed signals on valuation and sentiment, this is a moment to look closely at the numbers and decide where you stand. To weigh the potential upsides against the concerns in one place, review the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If you stop at one stock, you could miss opportunities that fit your style far better, so widen your search with screeners built to surface focused ideas.

• Target potential upside by zeroing in on companies that combine quality and attractive valuations using the 51 high quality undervalued stocks.
• Prioritise strength and resilience by turning to the solid balance sheet and fundamentals stocks screener (46 results) to spot businesses with sturdier financial foundations.
• Spot tomorrow's potential standouts early by scanning the screener containing 21 high quality undiscovered gems before they draw wider market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.